Altimmune, Inc. 8-K

What Happened
Altimmune, Inc. (ALT) filed a Form 8‑K on April 16, 2026 reporting that it amended its Amended and Restated Certificate of Incorporation to increase the number of authorized shares of common stock. The Certificate of Amendment, filed with the Delaware Secretary of State, raises authorized common shares from 200,000,000 to 400,000,000. The amendment was approved by holders of more than a majority of votes cast at Altimmune’s 2026 Annual Meeting of Shareholders.

Key Details

• Authorized common shares increased from 200,000,000 to 400,000,000.
• Certificate of Amendment filed with the Delaware Secretary of State on April 16, 2026.
• Amendment was approved by a majority of votes cast at the 2026 Annual Meeting of Shareholders.
• Form 8‑K was signed by CFO Gregory Weaver on April 16, 2026.

Why It Matters
This action changes Altimmune’s corporate charter to permit issuance of additional common stock in the future. It does not itself issue new shares or change outstanding share count, but gives the company flexibility for potential fundraising, acquisitions, equity compensation, or other corporate actions that require additional authorized shares. Investors should note the potential for future dilution if the company issues new shares, and watch for subsequent filings disclosing any planned issuances or use of the increased authorization.